Association between aldehyde dehydrogenase gene polymorphisms and the phenomenon of field cancerization in patients with head and neck cancer

Manabu Muto1,2,7, Mari Nakane1, Yoshiaki Hitomi2, Shigeru Yoshida3, Satoshi Sasaki4, Atsushi Ohtsu1, Shigeaki Yoshida1, Satoshi Ebihara5 and Hiroyasu Esumi2

1 Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwanoha 6-5-1, Kashiwa 277-8577,
2 Investigative Treatment Division, National Cancer Center Research Institute East, Kashiwa 277-8577,
3 Kaken Corp., Horimachi 1044, Mito 310-0903,
4 Epidemiology and Biostatistics Division, National Cancer Center Research Institute East, Kashiwa 277-8577,
5 Division of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, Japan


    Abstract
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
Patients with squamous-cell carcinoma in the head and neck (HNSCC) often develop second primary esophageal squamous-cell carcinomas (ESCC). In addition, widespread epithelial oncogenic alterations are also frequently observed in the esophagus and can be made visible as multiple Lugol-voiding lesions (multiple LVL) by Lugol chromoendoscopy. Multiple occurrences of neoplastic change in the upper aerodigestive tract have been explained by the concept of ‘field cancerization’, usually associated with repeated exposure to carcinogens such as alcohol and cigarette smoke. However, the etiology of second ESCC in HNSCC patients remains unclear and acetaldehyde, the first metabolite of ethanol, has been implicated as the ultimate carcinogen in alcohol-related carcinogenesis. We first investigated the relation between second ESCC and multiple LVL in 78 HNSCC patients. Multiple LVL and second ESCC were observed in 29 (37%) and 21 (27%) patients, respectively. All of the second ESCC were accompanied by multiple LVL. This may indicate that episodes of multiple LVL are precursors for second ESCC. We then examined the association of multiple LVL with the patients’ characteristics, including genetic polymorphisms of the alcohol metabolizing enzymes, alcohol dehydrogenase type 3 (ADH3) and aldehyde dehydrogenase type 2 (ALDH2). We also investigated acetaldehyde concentrations in the breath of 52 of the 78 patients. All the patients with multiple LVL were both drinkers and smokers. Multivariable logistic analysis showed that the inactive ALDH2 allele (ALDH2-2) was the strongest contributing factor for the development of multiple LVL (odds ratio 17.6; 95% confidence intervals 4.7–65.3). After alcohol ingestion, acetaldehyde in the breath was elevated to a significantly higher level in all patients with the ALDH2-2 allele than in those without it. The high levels of breath acetaldehyde were significantly modified by the slow-metabolizing ADH3-2 allele. These results reveal strong evidence for a gene–environmental interaction between the ALDH2-2 allele and alcohol consumption, for the risk of developing multiple LVL, resulting in the development of second ESCC in patients with HNSCC. Ultimately, increased local acetaldehyde exposure thus appears to be a critical determinant of the phenomenon of ‘field cancerization’.

Abbreviations: ADH, alcohol dehydrogenase; ALDH, aldehyde dehydrogenase; CI, confidence interval; ESCC, esophageal squamous cell carcinoma; HNSCC, squamous cell carcinoma in the head and neck; multiple LVL, multiple Lugol-voiding lesions; PCR–REP, polymerase chain reaction-restriction fragment length polymorphism.


    Introduction
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
Patients with HNSCC, especially in the oral cavity, oropharynx and hypopharynx, often develop second primary ESCC (15). In such patients, widespread epithelial oncogenic alterations, such as several grades of squamous epithelial dysplasia, also frequently occur in the upper aerodigestive tract including the esophagus (6,7). They are clinically detected as multiple Lugol-voiding lesions (multiple LVL) by Lugol chromoendoscopy (8), since Lugol-dye does not stain such lesions (9). These findings have been explained by the concept of ‘field cancerization’ proposed by Slaughter et al. (10), which is based on the hypothesis that repeated exposure to carcinogens contributes to the development of lesions. Although alcohol and cigarette smoke have been linked to this phenomenon (11,12), patients with HNSCC do not always develop second ESCC even if they consume alcohol and cigarettes. Identification of the etiology underlying the phenomenon of field cancerization might help to explain why some patients with HNSCC have a high likelihood of developing a second ESCC, and this will have a great impact on designing effective prevention, early diagnosis and therapeutic strategies.

There has been increasing evidence that acetaldehyde, the first metabolite of ethanol, rather than alcohol itself, may be responsible for the risk of developing alcohol-related cancers. Studies have suggested direct mutagenic and carcinogenic effects of acetaldehyde in vitro and in experimental animal models (1317). Acetaldehyde is formed by the oxidation of ethanol by alcohol dehydrogenase (ADH), and is eliminated by aldehyde dehydrogenase (ALDH) (18). In humans, the ADH3 and ALDH2 genes carry two alleles (ADH3-1 and ADH3-2, ALDH2-1 and ALDH2-2 alleles, respectively) with ethnic differences in the polymorphisms and different kinetic properties (1822). The ADH3-1 allele is present in 40–50% of Caucasians, while it is more predominant (~95%) in Japanese (23). In contrast, the ALDH2-2 allele is found in only orientals at a frequency of 50% (22). The ADH3-1 allele, coding for the rapidly acting ADH3, and the ALDH2-2 allele coding for inactive ALDH2, are closely associated with alcohol-related cancers in the upper aerodigestive tract (2429). As blood acetaldehyde concentrations after drinking in individuals carrying the ADH3-1 allele or the ALDH2-2 allele are reported to be significantly higher than in those lacking these alleles, an increase in acetaldehyde concentration appears to play a critical role in alcohol-related carcinogenesis (18,30). However, this raises an important question as to whether patients harboring the ADH3-1 or ALDH2-2 alleles can drink heavily: the accumulation of acetaldehyde plays a protective role against excessive alcohol consumption as it causes unpleasant reactions such as headache, nausea, vomiting, tachycardia, facial flushing, hypotension, and sleepiness (3133). To date, there have been no studies with biological measurements of acetaldehyde in relation to the risk of alcohol-related cancer to provide direct evidence that the accumulation of acetaldehyde is carcinogenic to human beings.

In this study, we found that a gene–environmental interaction between the ALDH2-2 allele and alcohol drinking is the most significant contributing factor for the development of multiple LVL, resulting in the development of second ESCC in patients with HNSCC. Ultimately, an increased acetaldehyde level is thus a critical determinant of the phenomenon of ‘field cancerization’.


    Materials and methods
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
Patients
This study was approved by the Institutional Review Board of the National Cancer Center, Tokyo. We excluded patients who had cancer at a site other than the oral cavity, oropharynx or hypopharynx or with histological findings other than squamous cell carcinoma. Seventy-eight consecutive Japanese patients with newly diagnosed HNSCC were entered into the study prospectively from September 1999 to July 2001. After obtaining written informed consent, demographic data were collected from the hospital charts and by interviews with patients.

The history of usage of tobacco and alcohol was carefully documented. The same questionnaire, which aimed to obtain detailed drinking and smoking habits, was used for the interview. Taking into account the different ethanol concentrations, alcohol consumption was estimated as the average amount of ingested alcohol for every drinking day in grams of pure alcohol per day. Indicators of tobacco use included the average number of cigarettes smoked per day, and the duration of smoking in years. The smoking index was calculated as the number of cigarettes smoked per day multiplied by the number of total smoking years. Drinkers and smokers were defined as patients who drank and smoked every day, respectively. Smokers who had ceased smoking for more than 5 years before being treated for HNSCC were categorized as ex-smokers, as in a previous report (34). Non-smokers and non-drinkers were defined as patients who never used or who only rarely used tobacco and alcohol, respectively.

Lugol chromoendoscopy
Lugol chromoendoscopy was performed using Lugol dye staining methods as described previously (8,35,36), using an electronic endoscope (Q230 or Q200, Olympus Optical, Tokyo, Japan). Lesions were defined as multiple LVL when numerous well-defined, irregular-shaped Lugol-voiding lesions were observed endoscopically throughout the entire esophageal mucosa after application of the Lugol dye solution (Figure 1Go). A single endoscopist (MM) evaluated the incidence of multiple LVL. Concomitant second ESCC was confirmed histologically using biopsy specimens.



View larger version (164K):
[in this window]
[in a new window]
 
Fig. 1. Multiple LVL. Numerous well-defined, irregular-shaped Lugol-voiding lesions were endoscopically observed throughout the entire esophageal mucosa after application of the Lugol dye solution.

 
Molecular analysis
To determine genetic polymorphism of the ADH3 and ALDH2 genes, genomic DNA was extracted from peripheral lymphocytes using a DNA isolation kit (Roche Diagnostics, Switzerland). Genetic polymorphism was analyzed by the polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP) method as described previously (8). For ADH3 genotyping, genomic DNA was initially digested with NlaIII (TOYOBO, Osaka, Japan) to prevent amplification of closely related ADH1 and ADH2 genes. The PCR products for ADH3 and ALDH2 genotyping were digested with SspI (TOYOBO, Osaka, Japan) and MboII (TOYOBO, Osaka, Japan) respectively, and separated on a 10% polyacrylamide gel. We divided the genotypes of ADH3 and ALDH2 into two groups: those homozygous for the ADH3-1 allele and those with the ADH3-2 allele; and those homozygous for the ALDH2-1 allele and with the ALDH2-2 allele, respectively.

Measurement of acetaldehyde levels
Previous reports have shown that acetaldehyde circulating in the blood can be expired (3739). If HNSCC patients expire high levels of acetaldehyde, direct exposure to acetaldehyde could play critical and specific roles in carcinogenesis in the mucosa of the upper aerodigestive tract. To assess the acetaldehyde levels in the breath, we asked participants to drink 200 ml of 6% ethanol in grapefruit juice over 10 min after at least 2 h of fasting. Among 78 patients enrolled in this study, 26 patients could not participate in this ‘acetaldehyde breath test’, because of severe dysphasia. Thus, the study population for this acetaldehyde breath test consisted of 52 patients. Breath samples were collected before drinking the alcohol, and 0, 10 and 30 min later. The test period and amount of alcohol required for ingestion to adequately measure acetaldehyde were previously assessed (unpublished data). Exhaled breath samples were obtained in collecting bags with a capacity of approximately 250 ml, which are used routinely for urea breath tests for Helicobacter pylori infection. Acetaldehyde levels in breath aliquots (1 ml each) were determined immediately by gas chromatography. The conditions for analysis were as follows: Porapack Q60/80 glass column (GL Science, Tokyo) 3 mm x 2 m; detector, flame ionization detector (FID); injection temperature, 200°C; column temperature, 150°C; detector temperature, 200°C; carrier gas (He) flow rate, 40 ml/min. Reproducibility of the measurement of acetaldehyde in the breath was determined by repetition of this test twice in six healthy volunteers: two subjects homozygous for ALDH2-1 and four subjects heterozygous for ALDH2-1/2-2. The investigator (MN) analyzing the genetic polymorphism was blinded to the results of the acetaldehyde breath test and endoscopic findings.

Statistical analysis
All statistical analyses were performed using the Stat View software package for Macintosh (Version 5; Abacus Concepts, Berkeley, CA). Quantitative data were compared using Student’s t-test. For categorical variables, we used Fisher’s exact test. A P-value of <0.05 was considered statistically significant. Logistic regression was used for the statistical comparisons of discrete variables between the patients with and without multiple LVL. Multiple logistic regression analysis was used to examine the multivariate-adjusted odds ratio for the development of multiple LVL in patients with HNSCC.


    Results
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
Study population
Table IGo shows the patients’ characteristics. The patients included 66 males and 12 females, with mean ± SD ages of 61 ± 8.4 years. The most common primary sites of tumors were the oral cavity and hypopharynx, and 68 of the 78 patients were drinkers (78%). All of the drinkers had a long-term history of alcohol drinking for more than 20 years. Fifty-three (68%) of the patients currently smoked cigarettes and all but one had a smoking-index history of >400. Seventeen (22%) of the patients were ex-smokers and eight (10%) were non-smokers.


View this table:
[in this window]
[in a new window]
 
Table I. Comparison of the characteristics of patients with HNSCC acording to presence or absence of multiple LVL
 
Correlation between multiple LVL and synchronous second ESCC
Using Lugol chromoendoscopy, we found evidence of multiple LVL and second ESCC in 29 (37%) and 21 (30%) of the patients, respectively (Table IGo). Patients with multiple LVL had a higher prevalence of second ESCC compared with patients without multiple LVL (72% vs. 0%, P < 0.0001).

Patient characteristics correlated with multiple LVL
To identify any patient characteristics correlated with the development of multiple LVL, we first compared gender, age, site of the primary tumor, alcohol consumption and smoking habits (Table IGo).

Age and gender were identical between the patients with and without multiple LVL. For primary tumors, the hypo- and oropharynx were the most prevalent sites in patients with multiple LVL. All of the patients with multiple LVL were smokers or ex-smokers, and a smoking index >1000 was closely associated with multiple LVL. As for drinking, all of the patients with multiple LVL were drinkers. Although weak but significant associations were observed in the amount of daily alcohol intake and duration of drinking habits between the patients with and without multiple LVL, these differences seemed to depend largely on the inclusion of non-drinkers. To examine the actual effects of drinking, we compared these factors among only drinkers, and no differences were seen.

To investigate the gene–environmental interaction with alcohol drinking for the risk of the development of multiple LVL, we compared the prevalence of the ADH3 and ALDH2 gene polymorphisms. The ALDH2-2 allele was significantly more prevalent in the patients with multiple LVL compared with those without multiple LVL (79% vs. 20%: P < 0.0001). In contrast, no differences were observed for ADH3 gene polymorphism.

Clinical and genetic variables correlated with the development of multiple LVL were determined using a univariate logistic regression analysis (Table IIGo). ALDH2 genotype (ALDH2-2 allele present) had the strongest statistical association with multiple LVL (odds ratio 15.0, 95% CI 4.80–46.55: P < 0.001). The primary site of the tumor and the smoking index were also significantly associated with multiple LVL (odds ratio 9.04 and 3.58; 95 % CI 2.92–27.94 and 1.36–9.39: P < 0.001 and <0.008, respectively). Although the ADH3-2 allele not the ADH3-1 allele showed a weak association with multiple LVL, the difference was not statistically significant (odds ratio 2.80; 95% CI 0.80–9.84: P = 0.11). Patient age, gender and daily alcohol consumption were not significantly associated with the development of multiple LVL.


View this table:
[in this window]
[in a new window]
 
Table II. Clinical and genetic variables associated with multiple LVL in patients with HNSCC (univariate logistic regression)
 
ALDH2 genotype, smoking index and site of primary tumor were then examined in a multivariate logistic regression model to define independent variables associated with the development of multiple LVL in HNSCC patients (Table IIIGo). In the multivariate analysis, ALDH2 genotype (ALDH2-2 allele present) was associated with the greatest overall risk for the development of multiple LVL (odds ratio 17.6; 95% CI 4.72–65.29: P < 0.0001). Smoking index (>=1000) and site of the primary tumor were also associated with the risk of the development of multiple LVL, with odds ratios of 6.4 (95% CI 1.65–25.15: P < 0.005) and 3.8 (95% CI, 0.99–14.57: P < 0.05), respectively.


View this table:
[in this window]
[in a new window]
 
Table III. Predictors of multiple LVL in patients with HNSCC by multivariate logistic regression
 
Assessing acetaldehyde levels in the breath
These results strongly suggest that the interaction between drinking and the ALDH2-2 allele is responsible for the development of multiple LVL in patients with HNSCC. To address these issues, we measured acetaldehyde concentrations in the breath of 52 patients (Figure 2Go). Thirty-three patients were homozygous for ALDH2-1 and the remaining 19 patients were heterozygotes. No acetaldehyde was detected in breath samples taken before drinking in any patients. Immediately after finishing drinking, the acetaldehyde levels in the breath were elevated to significantly higher levels in those patients who had the ALDH2-2 allele than in those homozygous for ALDH2-1 (P < 0.001). At 10 and 30 min after drinking, this high level of acetaldehyde persisted in all patients with the ALDH2-2 allele, even though it had already decreased to undetectable levels in those homozygous for the ALDH2-1 allele (P < 0.001). Thus, patients with the ALDH2-2 allele expired significantly higher concentrations of acetaldehyde after drinking.



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2. Acetaldehyde breath test. Acetaldehyde levels in expired breath are measured by gas chromatography. Each point represents one individual who was sampled several times: filled circles, subjects with the ALDH2-2 allele; open circles subjects lacking the ALDH2-2 allele.

 
Furthermore, ADH3 genotype modified the concentration of acetaldehyde in the breath. When the ADH3-2 allele was combined with the ALDH2-2 allele, the breath acetaldehyde concentration immediately after finishing drinking was significantly higher than in those without this allele among the ALDH2-2 allele carriers (Figure 3Go). This high acetaldehyde concentration that was modified by the ADH3-2 allele persisted for at least 30 min after finishing drinking (Figure 3Go).



View larger version (16K):
[in this window]
[in a new window]
 
Fig. 3. The combined influence of ADH3 and ALDH2 genotype on the acetaldehyde concentration in the breath. When the ADH3-2 allele was combined with the ALDH2-2 allele, the breath acetaldehyde concentration was higher than those without ADH3-1 allele among the ALDH2-2 allele carriers. (*P = 0.03, **P = 0.15, ***P = 0.07.)

 
It was also noted that acetaldehyde levels in the breath in patients with the ALDH2-2 allele showed significant individual differences. These differences had no direct relationship with body surface area, age, sex, or the drinking or smoking habits of each individual (data not shown).


    Discussion
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 
The mechanism of frequent occurrence of second ESCC in patients with HNSCC has been an important unresolved question, because the development of secondary tumors adversely affects the survival of those patients with HNSCC (4042). Although there have been numerous clinical reports regarding this phenomenon (15), the precise etiology remains unclear. The present data demonstrate a clear association between multiple LVL and second ESCC in patients with HNSCC. This finding suggests that episodes of multiple LVL are precursors of second ESCC in such patients. Therefore, the investigation on how multiple LVL develop could provide essential information about the etiology of the phenomenon of field cancerization.

We found a strong association between the development of multiple LVL and the ALDH2-2 allele in patients with HNSCC. In addition, estimation of the gene–environmental interaction with alcohol drinking demonstrated that only the drinkers developed multiple LVL. A previous case–control study also showed a strong gene and environmental interaction between the ALDH2-2 allele and heavy drinking for the risk of developing esophageal cancer (43). These results suggest that increased acetaldehyde produced in an interaction between the ALDH2-2 allele and drinking is responsible for the development of multiple LVL. Indeed, significantly higher acetaldehyde levels in the breath were detected in all patients with the ALDH2-2 allele compared with those without this allele. The results mean that there is no compensatory mechanism for eliminating acetaldehyde even after long-term alcohol consumption in those patients with the ALDH2-2 allele. Although this finding supports the hypothesis that acetaldehyde is associated with alcohol-related carcinogenesis, it is unknown why the patients harboring the ALDH2-2 allele are heavy drinkers despite the unpleasant reaction to acetaldehyde. To clarify this issue, further investigation is needed.

As inhalation or drinking of acetaldehyde produces nasal and laryngeal carcinomas in experimental animal models (13,16,17), our results imply that direct exposure of the mucosa via expiratory breath to high levels of acetaldehyde may be a critical event in the development of multiple LVL. These observations can also explain the mechanism of the phenomenon of field cancerization, providing strong evidence for the carcinogenicity of acetaldehyde.

We also observed a weak association between ADH3 gene polymorphism and the development of multiple LVL. Although Coutelle et al. (24) and Harty et al. (25) found a significant association between the ADH3-1 allele and cancers of the upper aerodigestive tract, this association has been controversial because other investigators did not find any such association (44,45). In the present study, the ADH3-2 allele not the ADH3-1 allele was weakly associated with the development of multiple LVL. In addition, harboring this allele actually increased the breath acetaldehyde concentration compared with those lacking this allele even in the ALDH2-2 allele carries. Although the reason was unknown, one possibility was that the combined effects on the alcohol metabolisms by the slow metabolizing ADH3-2 allele and the inactive ALDH2-2 allele might influence the breath acetaldehyde concentration. It would be interesting to investigate the combined influence of ADH3 and ALDH2 genotypes (or other genes) on the phenomenon of field cancerization. However, because of the small sample size of the study and the low frequency (about 5%) of the ADH3-2 allele in Japanese people (22), our results should be interpreted with care until confirmed by larger studies.

Even in those patients homozygous for the ALDH2-1 allele, six (13%) had multiple LVL in our study. As all of these were heavy drinkers and smokers, alcohol and smoking were at least associated with the development of multiple LVL. Although we cannot adequately explain why they developed multiple LVL, it will be interesting to investigate this issue, because the phenomenon of field cancerization in the patients with HNSCC is also seen in Caucasians who do not have any polymorphism in the ALDH2 gene.

We found that a cigarette smoking index of >1000 is also an independent risk factor for developing multiple LVL. Because the carcinogenic effect of smoking has been established conclusively (46), the result indicates that smoking modifies the risk of the development of multiple LVL. In addition, as cigarette smoke contains significant amounts of acetaldehyde together with other various carcinogens (47,48), the combination of heavy smoking with drinking may partly increase regional acetaldehyde levels in the respiratory tract.

It should be noted that this study focused on those patients with HNSCC, because the phenomenon of field cancerization frequently occurs among them, but not in the general population. To date, it is unknown why this phenomenon occurs. In this limited study, we found that those with a tumor in the oro- or hypopharynx showed a significant higher odds ratio of developing multiple LVL compared with those with a tumor at other sites. If susceptibility to HNSCC is indeed associated with the phenomenon of field cancerization, further investigation is needed to understand the mechanism more clearly.

In summary, the present study reveals strong evidence for genetic and environmental interactions between the ALDH2-2 allele, the ADH3-2 allele and alcohol drinking, for the risk of developing widespread oncogenic epithelial alterations, resulting in the development of secondary ESCC in patients with HNSCC. Ultimately, increased local acetaldehyde exposure is a critical determinant of the phenomenon of field cancerization. This result may provide a new intervention strategy for the prevention of multiple cancers in the upper aerodigestive tract in high-risk populations.


    Notes
 
7 To whom correspondence should be addressed Email: mmuto{at}east.ncc.go.jp Back


    Acknowledgments
 
This work was supported in part by Grants-in-Aid for Cancer Research (10–25 and 10–36) and a Grant for the Second-term Comprehensive Ten-Year Strategy for Cancer Control from the Ministry of Health and Welfare of Japan. We thank all of the participants in this study. We are very grateful to Katsuyoshi Tatenuma and Kazunari Takagi (Kaken, Corp.) for their expert technical assistance.


    References
 Top
 Abstract
 Introduction
 Materials and methods
 Results
 Discussion
 References
 

  1. Goldstein,H.M. and Zornoza,J. (1978) Association of squamous cell carcinoma of the head and neck with cancer of the esophagus. Am. J. Roentgenol., 131, 791–794.[ISI][Medline]
  2. Weaver,A., Fleming,S.M., Knechtges,T.C. and Smith,D. (1979) Triple endoscopy: a neglected essential in head and neck cancer. Surgery, 86, 493–496.[ISI][Medline]
  3. Chon,A.M. and Peppard,S.B. (1980) Multiple primary malignant tumors of the head and neck. Am. J. Otolaryngol., 1, 411–417.[Medline]
  4. Shapshay,S.M., Hong,W.K., Fried,M.P., Sismanis,A., Vaughan,C.W. and Strong,S. (1980) Simultaneous carcinomas of the esophagus and upper aerodigestive tract. Otolaryngol. Head Neck Surg., 88, 373–377.[ISI][Medline]
  5. Mcguilt,W.F., Matthews,B. and Koufman,J.A. (1982) Multiple simultaneous tumors in patients with head and neck cancer, a prospective sequential panendoscopic study. Cancer, 50, 1195–1199.[ISI][Medline]
  6. Nakanishi,Y., Ochiai,A., Yoshimura,K., Kato,H., Shimoda,T., Yamaguchi,H., Tachimori,Y., Watanabe,H. and Hirohashi,S. (1998) The clinicopathologic significance of small areas unstained by lugol’s iodine in the mucosa surrounding resected esophageal carcinoma: An analysis of 147 cases. Cancer, 82, 1454–1459.[ISI][Medline]
  7. Shiozaki,H., Tahara,H., Kobayashi,K., et al. (1990) Endoscopic screening of early esophageal cancer with the lugol dye method in patients with head and neck cancers. Cancer, 60, 2068–2071.
  8. Muto,M., Hitomi,Y., Ohtsu,Y., Ebihara,S., Yoshida,S. and Esumi,H. (2000) Association of aldehyde dehydrogenase 2 gene polymorphism with multiple esophageal dysplasia in head and neck cancer patients. Gut, 47, 256–261.[Abstract/Free Full Text]
  9. Mori,M., Adachi,Y., Matsushima,T., Mtsuda,H., Kuwano.,H. and Sugimachi,K. (1993) Lugol staining pattern and histology of esophageal lesions. Am. J. Gastroenterol., 88, 701–705.[ISI][Medline]
  10. Slaughter,D.P., Southwick,H.W. and Smejkal,W. (1953) ‘Field cancerization’ in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer, 6, 963–968.[ISI][Medline]
  11. Hiyama,T., Sato,T., Yoshino,K., Tsukuma,H., Hanai,A. and Fujimoto,I. (1992) Second primary cancer following laryngeal cancer with special reference to smoking habits. Jpn. J. Cancer Res., 83, 334–339.[ISI][Medline]
  12. Morita,M., Kusano,H., Ohno,S., Saguache,K., Seo,Y., Tomida,H., Furusawa,M. and Nakashima,T. (1994) Multiple occurrence of carcinoma in the upper aerodigestive tract associated with esophageal cancer: reference to smoking, drinking and family history. Int. J. Cancer, 58, 207–210.[ISI][Medline]
  13. IARC (1985) Allyl compounds, aldehyde, epoxies and peroxides. In: The Evaluation of the Carcinogenic Risk of Chemicals to Humans. IARC Monograph No. 36, pp. 101–132. IARC, Lyon.
  14. Delanco,V.L. (1988) A mutagenicity assessment of acetaldehyde. Mutat. Res., 195, 1–20.[ISI][Medline]
  15. Helander,A. and Lindahl-Keissling,K. (1991) Increased frequency of acetaldehyde-induced sister chromatic exchanges in human lymphocytes treated with an aldehyde dehydrogenase inhibitor. Mutat. Res., 264, 103–107.[ISI][Medline]
  16. Woutersen,R.A., Appelman.,L.M., Van Garderen-Hoetmer,A. and Feron,V.J. (1986) Inhalation toxicity of acetaldehyde in rat. III. Carcinogenicity study. Toxicology, 41, 213–231.[ISI][Medline]
  17. Feron,V.J., Kruysse,A. and Woutersen,R.A. (1982) Respiratory tract tumors in hamsters exposed to acetaldehyde vapour alone or simultaneously to benzo[a]pyrene or diethylnitrosamine. Eur. J. Cancer Clin. Oncol., 18, 13–31.[ISI][Medline]
  18. Bosron,W.F. and Li,T.K. (1986) Genetic polymorphism of human liver alcohol and aldehyde dehydrogenases and their relationship to alcohol metabolism and alcoholism. Hepatology, 6, 502–510.[ISI][Medline]
  19. Yoshida,A., Huang,Y. and Ikawa,M. (1984) Molecular abnormality of an inactive aldehyde dehydrogenase variant commonly found in Orientals. Proc. Natl Acad. Sci. USA, 81, 258–261.[Abstract]
  20. Crabb,D.W., Edenberg,H.G., Bosron,W.F. and Li,T.K. (1989) Genotypes for aldehyde dehydrogenase deficiency and alcohol sensitivity. The inactive ALDH2-2 allele is dominant. J. Clin. Invest., 83, 314–316.[ISI][Medline]
  21. Harada,S. and Zhang,S. (1993) New strategy for detection of ALDH2 mutant. Alcohol Alcoholism (Suppl.) 1A, 11–13.
  22. Harada,S., Misawa,S., Agarwal,D.P. and Goedde,H.W. (1980) Liver alcohol dehydrogenase and aldehyde dehydrogenase in the Japanese: Isozyme variation and its possible role in alcohol intoxication. Am. J. Hum. Genet., 32, 8–15.[ISI][Medline]
  23. Bosron,W.F., Lumeng,L. and Li,T.K. (1988) Genetic polymorphism of enzymes of alcohol metabolism and susceptibility to alcohol liver disease. Mol. Aspects Med. 10, 147–158.
  24. Coutelle,C., Ward,P.J., Fleury,B., Quattrocchi,P., Chambrin,H., Iron,A., Couzigou,P. and Cassaigne,A. (1997) Laryngeal and oropharyngeal cancer and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. Hum. Genet., 99, 319–325.[ISI][Medline]
  25. Harty,L.C., Caporaso,N.E., Hayes,R.B., et al. (1997) Alcohol dehydrogenase 3 genotype and risk of oral cavity and pharyngeal cancers. J. Natl Cancer Inst., 89, 1698–1705.[Abstract/Free Full Text]
  26. Yokoyama,A., Muramatsu,T., Ohmori,T., et al. (1996) Multiple primary esophageal and concurrent upper aerodigestive tract cancer and the aldehyde dehydrogenase-2 genotype of Japanese alcoholics. Cancer, 77, 1986–1990.[ISI][Medline]
  27. Hori,H., Kawano,T., Endo,M. and Yuasa,Y. (1997) Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and human esophageal squamous cell carcinoma susceptibility. J. Clin. Gastroenterol., 25, 568–575.[ISI][Medline]
  28. Yokoyama,A, Muramatsu,T., Ohmori,T., et al. (1998) Alcohol-related cancers and aldehyde dehydrogenase-2 in Japanese alcoholics. Carcinogenesis, 19, 1383–1387.[Abstract]
  29. Nomura,T., Noda,H., Shibahara,T., Yokoyama,A., Muramatsu,T. and Ohmori,T. (2000) Aldehyde dehydrogenase 2 and glutathione S-transferase M1 polymorphism in relation to the risk for oral cancer in Japanese drinkers. Oral Oncol., 36, 42–46.[ISI][Medline]
  30. Yamamoto,K., Ueno,Y., Mizoi,Y. and Tatsuno,Y. (1993) Genetic polymorphism of alcohol and aldehyde dehydrogenase and the effects on alcohol metabolism. Jpn. J. Alc. Drug Depend., 28, 13–25.
  31. Wartburg,J.V., Buhler,R., Maring,J.A. and Pestalozzi,D. (1983) The polymorphisms of alcohol and aldehyde dehydrogenase and their significance for acetaldehyde toxicity. Pharmacol. Biochem. Behav., 18, 123–125.[ISI][Medline]
  32. Sun,F., Tsuritani,I., Honda,R., Ma,Z.Y. and Yamada,Y. (1999) Association of genetic polymorphisms of alcohol-metabolizing enzymes with excessive alcohol consumption in Japanese men. Hum. Genet., 105, 295–300.[ISI][Medline]
  33. Okamoto,K., Murawaki,Y., Yuasa,I. and Kawasaki,H. (2001) Effect of ALDH2 and CYP2E1 gene polymorphisms on drinking behavior and alcoholic liver disease in Japanese male workers. Alcohol Clin. Exp. Res., 25, 19S–23S.[ISI][Medline]
  34. Homann,N., Tillonen,J., Meurman,J.H., Rintamaki,H., Lindqvist,C., Rautio,M., Jousimies-Somer,H. and Salaspuro,M. (2000) Increased salivary acetaldehyde levels in heavy drinkers and smokers: a microbiological approach to oral cavity cancer. Carcinogenesis, 21, 663–668.[Abstract/Free Full Text]
  35. Dawsey,M.D., Fleischer,D.E., Wang,G.O., et al. (1998) Mucosal iodine staining improves endoscopic visualization of squamous dysplasia and squamous cell carcinoma of the esophagus in Linxian, China. Cancer, 83, 220–231.[ISI][Medline]
  36. Inoue,H., Rey,J.F. and Lightdale,C. (2001) Lugol chromoendoscopy for esophageal squamous cell cancer. Endoscopy, 33, 75–79.[ISI][Medline]
  37. Freund,G. and O’Hollaren,P. (1965) Acetaldehyde concentrations in alveolar air following a standard dose of ethanol in man. J. Lipid Res., 6, 471–477.[Abstract/Free Full Text]
  38. Fukunaga,T., Yamamoto,K., Adachi,J., Ueno,Y. and Mizoi,Y. (1989) Partition ratio of acetaldehyde between blood and breath after ethanol consumption. Jpn. J. Alcohol Drug. Depend., 24, 405–416.
  39. Wong,M.K.C., Scott,B.K. and Peterson,C.M. (1992) Breath acetaldehyde following ethanol consumption. Alcohol, 9, 189–192.[ISI][Medline]
  40. Cooper,J.S., Pajak,T.F., Rubin,P., et al. (1989) Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int. J. Radiat. Oncol. Biol. Phys., 17, 449–456.[ISI][Medline]
  41. Jones,A.S., Morar,P., Phillips,D.E., Field,J.K., Husband,D. and Helliwell,T.R. (1995)Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer, 75, 1343–1353.[ISI][Medline]
  42. Erkal,H.S., Mendenhall,W.M., Amdur,R.J., Villaret,D.B. and Stringer,S.P. (2001) Synchronous and metachronous squamous cell carcinomas of the head and neck mucosal sites. J. Clin. Oncol., 19, 1358–1362.[Abstract/Free Full Text]
  43. Matsuo,K., Hamajima,N., Shinoda,M., Hatooka,S., Inoue,M., Takezaki,T. and Tajima,K. (2001) Gene–environment interaction between an aldehyde dehydrogenase-2 (ALDH2) polymorphism and alcohol consumption for the risk of esophageal cancer. Carcinogenesis, 22, 913–916.[Abstract/Free Full Text]
  44. Bouchardy,C., Hirvonen,A., Coutelle,C., Ward,P.J., Dayer,P. and Benhamou,S. (2000) Role of alcohol dehydrogenase 3 and cytochrome P-4502E1 genotypes in susceptibility to cancers of the upper aerodigestive tract. Int. J. Cancer, 87, 734–740.[ISI][Medline]
  45. Olshan,A.F., Weissler,M.C., Watson,M.A. and Bell,D.A. (2001) Risk of head and neck cancer and the alcohol dehydrogenase 3 genotype. Carcinogenesis, 22, 57–61.[Abstract/Free Full Text]
  46. Tomatis,L., Aitio,A., Day,N.E., Heseltine,E., Kaldor,J., Miller,A.B., Parkin,D.M. and Riboli,E. (1990) Cancer: Causes, Occurrence and Control. IARC Scientific Publications No. 100. IARC, Lyon.
  47. Hoberman,H.D. and San George,R.C. (1988) Reaction of tobacco smoke aldehyde with human hemoglobin. J. Biochem. Toxicol., 3, 105–119.[ISI][Medline]
  48. Houlgate,P.R., Dhingra,K.S., Nash,S.J. and Evans,W.H. (1989) Determination of formaldehyde and acetaldehyde in mainstream of cigarette smoke by high performance liquid chromatography. Analyst, 114, 355–360.[ISI][Medline]
Received April 24, 2002; revised June 27, 2002; accepted June 28, 2002.